Advertisement

Plenary Lecture at SABCS: Researchers Continue to Explore HER2 Blockade Strategies

Evidence-based clinical practice has evolved and the search for how best to blockade the HER2 receptor in HER2+ breast cancer continues, said Mothaffer Rimawi, MD, of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston, TX. In a plenary lecture, Dr Rimawi reviewed HER2 therapies for curative intent over the past decade.

 Cancer Therapy Advisor

click me